A First-in-Man Study of the Firesorb BVS (FUTURE-I)

NCT02659254 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DEVICE: Sirolimus Target Eluting Bioresorbable Vascular Scaffold

Sponsor

Shanghai MicroPort Medical (Group) Co., Ltd.